Catalyst Pharmaceutical Partners (CPRX)
NASDAQ:CPRX
Want to see CPRX full AI Analyst Report?
CPRX Stock Chart & Stats
$26.26
-$0.35(-1.79%)
At close: 4:00 PM EST
$26.26
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $32.56
Previous CloseN/A
Volume328.11K
Average Volume (3M)3.06M
Market Cap
$3.83B
Enterprise Value$3.07B
Total Cash (Recent Filing)$755.86M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)17.3
Beta0.69
Next Earnings
Aug 12, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.80
Shares Outstanding122,380,990
10 Day Avg. Volume2,605,087
30 Day Avg. Volume3,055,176
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.99
Price to Sales (P/S)4.85
P/FCF Ratio13.68
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue5.14
Enterprise Value/Gross Profit6.24
Enterprise Value/Ebitda9.78
Forecast
1Y Price Target
$32.40Price Target Upside23.38% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.92
Revenue Forecast (FY)$632.92M
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained very high gross and net margins indicate durable pricing power and low incremental cost structure typical of specialty pharmaceuticals. This margin profile supports robust cash generation and reinvestment capacity, cushioning the business versus cyclical sales swings.
Conservative Balance Sheet & Cash GenerationExtremely low leverage and a large cash balance with free cash flow roughly matching net income provide financial flexibility for lifecycle studies, commercialization support, BD acquisitions, or to withstand reimbursement pressures without near-term financing risk.
Extended FIRDAPSE Exclusivity VisibilityThe litigation settlement materially extends the window free from that generic entrant through 2035, preserving the core FIRDAPSE revenue stream and allowing multi-year planning, investment in patient ID and lifecycle work, and predictable cash flows for acquirers or shareholders.
Bears Say
Decelerating Revenue GrowthRevenue growth has slowed sharply from prior years to near-flat TTM levels, indicating the core commercial ramp may be maturing. Without new indications, durable label expansions, or successful BD deals, top-line stagnation could constrain long-term earnings growth and return expansion.
Ongoing IRA Gross-to-Net PressureRising, structural IRA-driven gross-to-net erosion on Medicare Part D reduces net realized prices over multiple years. This recurring headwind directly lowers margins and cash flow per unit sold and is not easily offset by pricing, raising medium-term sustainability risks to net revenue.
Product Concentration & FYCOMPA ErosionMaterial post-LOE decline at FYCOMPA highlights reliance on a small number of products. Concentration amplifies sensitivity to exclusivity losses or label limitations; durable growth depends on AGAMREE scale, FIRDAPSE protection, or successful external BD to diversify revenue sources.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $19.05 and its highest was $32.56 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $3.83B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on May 11, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.475 by $0.025.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.47.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 122,380,990 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.5 in its last earnings report, beating expectations of $0.475. Following the earnings report the stock price went down -0.032%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.40 (23.38% Upside)
$32.40 (23.38% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.28%
12-Months-Change
Fundamentals
Return on Equity
23.65%
Trailing 12-Months
Asset Growth
26.27%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$32.40
▲(23.38% Upside)
Technical Analysis
Ownership Overview
5.52% Insiders
18.78% Mutual Funds
16.84% Other Institutional Investors
30.51% Public Companies and Individual Investors